1. Home
  2. LGCB vs MBRX Comparison

LGCB vs MBRX Comparison

Compare LGCB & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGCB

Linkage Global Inc

HOLD

Current Price

$0.55

Market Cap

15.7M

Sector

N/A

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.49

Market Cap

13.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGCB
MBRX
Founded
2011
2015
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
13.4M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
LGCB
MBRX
Price
$0.55
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
127.9K
87.1K
Earning Date
01-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.25
52 Week High
$3.10
$7.98

Technical Indicators

Market Signals
Indicator
LGCB
MBRX
Relative Strength Index (RSI) 17.73 48.26
Support Level N/A $2.24
Resistance Level $2.23 $2.58
Average True Range (ATR) 0.12 0.14
MACD -0.03 0.01
Stochastic Oscillator 11.85 51.58

Price Performance

Historical Comparison
LGCB
MBRX

About LGCB Linkage Global Inc

Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: